Background
Methods
Patients and tissue samples
Immunohistochemistry
Interpretation of PD-L1 expression by immunohistochemistry
TC score | TC definition | IC score | IC definition |
---|---|---|---|
TC 0 | < 1% | IC 0 | < 1% |
TC 1 | 1% > 5% | IC 1 | 1 > 5% |
TC 2 | 5% < 50% | IC 2 | 5 < 10% |
TC 3 | ≥50% | IC 3 | ≥10% |
Cell lines
Flow cytometry analysis
Results
Clinicopathological features
PD-L1 protein status and characterization of immune contexture by IHC
ID | Histotype | Fusion Trascript | PD-L1 IHC | Comments | Status | T | N | M | IRS | Outcome | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TC score | IC score | ||||||||||||
Clone SP142 | Clone 22C3 | Clone SP142 | Clone 22C3 | ||||||||||
RMS1 | ERMS | negative | 0 | 0 | 2 | 2 | IC only outside tumor | In therapy | T2B | N0 | M1 | 4 | DOD |
RMS2 | ARMS | PAX7-FOXO1 | 0 | 0 | 0 | 0 | Pre-treated | T1 | N0 | M0 | 1 | DOD | |
RMS3 | ERMS | negative | 0 | 0 | 0 | 0 | In therapy | T2B | N0 | M1 | 4 | DOD | |
RMS4 | ARMS | negative | 0 | 0 | 0 | 0 | At diagnosis | T2B | N0 | M1 | 4 | DOD | |
RMS5 | ERMS | negative | 0 | 0 | 0 | 0 | At diagnosis | T2A | N0 | M1 | 4 | 1°RC | |
RMS6 | ARMS | negative | 0 | 0 | 3 | 3 | IC outside and infiltrating tumor | At diagnosis | T2A | N1 | M1 | 4 | DOD |
RMS7 | ARMS | PAX3-FOXO1 | 0 | 0 | 1 | 1 | Few cells in IC outside and infiltrating tumor | At diagnosis | T1A | N0 | M1 | 4 | DOD |
RMS8 | ERMS | negative | 0 | 0 | 2 | 2 | IC only outside tumor | Pre-treated | T2B | N0 | M0 | 3 | 1°RC |
RMS9 | ERMS | negative | 0 | 0 | 3 | 3 | IC outside and infiltrating tumor | At diagnosis | T2B | N0 | M0 | 3 | 1°RC |
RMS10 | ARMS | negative | 0 | 0 | 2 | 2 | IC only outside tumor | Pre-treated | T2B | N0 | M0 | 3 | 2°RC |
RMS11 | RMS | negative | 0 | 0 | 0 | 0 | At diagnosis | T2B | N1 | M0 | 3 | DOD | |
RMS12 | ARMS | PAX7-FOXO1 | 0 | 0 | 2 | 2 | IC only outside tumor | At diagnosis | T2B | N1 | M0 | 3 | 1°RC |
RMS13 | ARMS | PAX7-FOXO1 | 0 | 0 | 3 | 3 | IC outside and infiltrating tumor | Pre-treated | T2A | N0 | M1 | 3 | DOD |
RMS14 | ARMS | PAX3-FOXO1 | 0 | 0 | 0 | 0 | At diagnosis | T1A | N0 | M1 | 4 | DOD | |
RMS15 | ERMS | negative | 0 | 0 | 2 | 2 | IC only infiltrating tumor | At diagnosis | T1A | N0 | M0 | 3 | 1°RC |
RMS16 | ARMS | PAX3-FOXO1 | 0 | 0 | 3 | 3 | IC outside and infiltrating tumor | At diagnosis | T2B | N1 | M0 | 3 | 1°RC |
RMS17 | ARMS | PAX3-FOXO1 | 0 | 0 | 0 | 0 | At diagnosis | T2B | N1 | M1 | 4 | DOD | |
RMS18 | ERMS | negative | 0 | 0 | 0 | 0 | At diagnosis | T2B | N0 | M0 | 3 | 1°RC | |
RMS19 | ERMS | negative | 0 | 0 | 2 | 2 | IC outside and infiltrating tumor | post-treatment | T2B | N0 | M0 | 3 | 1°RC |
RMS20 | ARMS | negative | 0 | 0 | 0 | 0 | post treated | T1A | N0 | M0 | 3 | 1°RC | |
RMS21 | ERMS | negative | 0 | 0 | 2 | 2 | IC outside and infiltrating tumor | post-treatment | T2B | N1 | M0 | 3 | DOD |
RMS22 | ERMS | negative | 0 | 0 | 2 | 2 | IC outside and infiltrating tumor | At diagnosis | T2B | N0 | M0 | 3 | 1°RC |
RMS23 | ERMS | negative | 0 | 0 | 3 | 3 | IC outside and infiltrating tumor | post-treatment | T2B | N0 | M0 | 3 | 1°RC |
RMS24 | ERMS | negative | 0 | 0 | 0 | 0 | At diagnosis | T2B | N0 | M0 | 3 | 1°RC | |
RMS25 | ERMS | negative | 0 | 0 | 2 | 2 | IC outside and infiltrating tumor | post-treatment | T2B | N0 | M0 | 3 | 1°RC |
PD-L1 expression by flow cytometry in cell lines
ID # | Cell line | Fusion Trascript | PD-L1 (IHC) | Flow Cytometry | PD-L1 (IHC) | |
---|---|---|---|---|---|---|
FFPE tissue | DERIVED CELL LINE | CYTOBLOCK (cell line) | ||||
TC score | IC score | % TC | ||||
RMS12 | RMS-GD | PAX7-FOXO1 | 0 | 2 | 2,10% | 0 |
RMS13 | RMS-ME | PAX7-FOXO1 | 0 | 3 | 1,93% | 0 |
RMS14 | RMS-GJ | PAX3-FOXO1 | 0 | 0 | 5,55% | 0 |
RMS15 | RMS-SG | negative | 0 | 2 | 2,83% | 0 |
RMS16 | RMS-BI | PAX3-FOXO1 | 0 | 3 | 12,25% | 1–5 TC |